Published in Scand J Gastroenterol on March 01, 2001
Efficacy of the vaccination in inflammatory bowel disease. World J Gastroenterol (2013) 1.12
Updates in vaccination: recommendations for adult inflammatory bowel disease patients. World J Gastroenterol (2015) 0.82
Vaccination strategies in patients with IBD. Nat Rev Gastroenterol Hepatol (2013) 0.81
Characterization of Serum Cytokine Profile in Predominantly Colonic Inflammatory Bowel Disease to Delineate Ulcerative and Crohn's Colitides. Clin Med Insights Gastroenterol (2015) 0.81
Vaccination issues in patients with inflammatory bowel disease receiving immunosuppression. Gastroenterol Hepatol (N Y) (2012) 0.79
Immunogenicity and mechanisms impairing the response to vaccines in inflammatory bowel disease. World J Gastroenterol (2015) 0.76
Immunizations in children with inflammatory bowel disease treated with immunosuppressive therapy. Gastroenterol Hepatol (N Y) (2014) 0.75
Vaccinating Patients With Inflammatory Bowel Disease. Gastroenterol Hepatol (N Y) (2016) 0.75
Preventative Care in the Patient with Inflammatory Bowel Disease: What Is New? Dig Dis Sci (2016) 0.75
Bacteriotherapy for chronic relapsing Clostridium difficile diarrhoea in six patients. Lancet (1989) 4.44
Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines. J Cell Physiol (1992) 3.15
Prophylactic effect of cimetidine in duodenal ulcer disease. Br Med J (1978) 2.91
The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res (2000) 2.09
Cimetidine in patients with gastric ulcer: a multicentre controlled trial. Br Med J (1977) 2.08
Effect of omeprazole and cimetidine on duodenal ulcer. A double-blind comparative trial. N Engl J Med (1985) 1.98
A pragmatic trial of cimetidine in duodenal ulcer patients. Scand J Gastroenterol (1977) 1.96
High glucose impairs superoxide production from isolated blood neutrophils. Intensive Care Med (2003) 1.88
In vivo profiles of eicosanoids in ulcerative colitis, Crohn's colitis, and Clostridium difficile colitis. Gastroenterology (1988) 1.86
High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res (1993) 1.86
Independent prognostic value of eosinophil and mast cell infiltration in colorectal cancer tissue. J Pathol (1999) 1.86
Effects of topical 5-aminosalicylic acid and prednisolone on prostaglandin E2 and leukotriene B4 levels determined by equilibrium in vivo dialysis of rectum in relapsing ulcerative colitis. Gastroenterology (1986) 1.67
Serum cystatin C, a new marker of glomerular filtration rate, is increased during malignant progression. Clin Chem (1998) 1.65
Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis. J Natl Cancer Inst (1999) 1.64
Colonic azodisalicylate metabolism determined by in vivo dialysis in healthy volunteers and patients with ulcerative colitis. Gastroenterology (1984) 1.62
Preoperative plasma plasminogen activator inhibitor type-1 and serum C-reactive protein levels in patients with colorectal cancer. The RANX05 Colorectal Cancer Study Group. Ann Surg Oncol (2000) 1.58
Serum YKL-40 and colorectal cancer. Br J Cancer (1999) 1.57
Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res (1994) 1.55
Soluble vascular endothelial growth factor levels in patients with primary colorectal carcinoma. The Danish RANX05 Colorectal Cancer Study Group. Eur J Surg Oncol (2000) 1.48
Activation of nuclear factor kappaB in colonic mucosa from patients with collagenous and ulcerative colitis. Gut (2005) 1.43
Saturation kinetics applied to in vitro effects of low prostaglandin E2 and F 2 alpha concentrations on ion transport across human jejunal mucosa. Gastroenterology (1980) 1.39
Involvement of 5-hydroxytryptamine, prostaglandin E2, and cyclic adenosine monophosphate in cholera toxin-induced fluid secretion in the small intestine of the rat in vivo. Gastroenterology (1989) 1.39
The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients. Cancer Res (1998) 1.38
Prostaglandin E2 in jejunal fluids and its potential diagnostic value for selecting patients with indomethacin-sensitive diarrhoea. Eur J Clin Invest (1981) 1.34
Review article: the treatment of inflammatory bowel disease with 6-mercaptopurine or azathioprine. Aliment Pharmacol Ther (2001) 1.33
Expression of Toll-like receptor 9 and response to bacterial CpG oligodeoxynucleotides in human intestinal epithelium. Clin Exp Immunol (2005) 1.32
Colonic transport of water and electrolytes in a patient with secretory diarrhea due to collagenous colitis. Dig Dis Sci (1983) 1.31
Cysteine proteinase inhibitors stefin A, stefin B, and cystatin C in sera from patients with colorectal cancer: relation to prognosis. Clin Cancer Res (2000) 1.31
Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma. Cancer Res (1994) 1.28
High preoperative plasma tissue inhibitor of metalloproteinase-1 levels are associated with short survival of patients with colorectal cancer. Clin Cancer Res (2000) 1.27
Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness. Clin Exp Metastasis (1996) 1.27
ELISA determination of soluble urokinase receptor in blood from healthy donors and cancer patients. Clin Chem (1997) 1.26
Tissue inhibitor of metalloproteinases-1 in breast cancer. Endocr Relat Cancer (2005) 1.24
Quantitation of TIMP-1 in plasma of healthy blood donors and patients with advanced cancer. Br J Cancer (1999) 1.24
Differences in transferrin response and numbers of transferrin receptors in rat and human mammary carcinoma lines of different metastatic potentials. J Cell Physiol (1993) 1.23
Expression of nitric oxide synthases and effects of L-arginine and L-NMMA on nitric oxide production and fluid transport in collagenous colitis. Gut (2001) 1.22
Receptor for urokinase is present in tumor-associated macrophages in ductal breast carcinoma. Cancer Res (1993) 1.22
Simultaneous measurement of electrical polarization and electrolyte transport by the entire normal and inflamed human colon during in vivo perfusion. Scand J Gastroenterol (1973) 1.22
Selective 5-lipoxygenase inhibition in ulcerative colitis. Lancet (1990) 1.21
Effect of azodisal sodium and sulphasalazine on ileostomy output of fluid and PGE2 and PGF2 alpha in subjects with a permanent ileostomy. Gut (1986) 1.20
Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer. Clin Cancer Res (1995) 1.19
Progression of human breast cancer cells from hormone-dependent to hormone-independent growth both in vitro and in vivo. Proc Natl Acad Sci U S A (1989) 1.19
Review article: the potential role of nitric oxide in chronic inflammatory bowel disorders. Aliment Pharmacol Ther (1999) 1.17
Soluble urokinase plasminogen activator receptor in plasma of patients with inflammatory rheumatic disorders: increased concentrations in rheumatoid arthritis. Ann Rheum Dis (1999) 1.15
Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn's disease. Gut (2001) 1.15
Soluble vascular endothelial growth factor in various blood transfusion components. Transfusion (1999) 1.14
Presence of urokinase-type plasminogen activator receptor in urine of cancer patients and its possible clinical relevance. Lab Invest (1999) 1.10
Comparison of radioimmunological determinations with gas chromatography mass spectrometry dosage. A study of PGE2 and PGF2alpha in gastrointestinal fluids. Biomed Mass Spectrom (1983) 1.09
Electrolyte transport capacity and electrical potentials of the normal and the inflamed human rectum in vivo. Scand J Gastroenterol (1973) 1.08
Gastric bicarbonate secretion and release of prostaglandin E2 are increased in duodenal ulcer patients but not in Helicobacter pylori-positive healthy subjects. Scand J Gastroenterol (1996) 1.08
Comparison of ranitidine and high-dose antacid in the treatment of prepyloric or duodenal ulcer. A double-blind controlled trial. Scand J Gastroenterol (1985) 1.07
Increased jejunal prostaglandin E2 concentrations in patients with acute cholera. Gut (1985) 1.06
Ultrasonic scanning in diagnosis of abdominal disease. Acta Chir Scand (1968) 1.06
The relationship between sodium fluxes and electrical potentials across the normal and inflamed human rectal wall in vivo. Acta Med Scand (1973) 1.06
Significance of calcium for the prostaglandin E2-mediated secretory response to 5-hydroxytryptamine in the small intestine of the rat in vivo. Gastroenterology (1986) 1.04
Superoxide production and expression of NAD(P)H oxidases by transformed and primary human colonic epithelial cells. Gut (2003) 1.04
A cleaved form of the receptor for urokinase-type plasminogen activator in invasive transplanted human and murine tumors. Int J Cancer (1994) 1.04
Expression of c-ets-1 mRNA is associated with an invasive, EMT-derived phenotype in breast carcinoma cell lines. Clin Exp Metastasis (1997) 1.03
TIMP-1 gene deficiency increases tumour cell sensitivity to chemotherapy-induced apoptosis. Br J Cancer (2006) 1.02
In vivo effects of orally administered prednisolone on prostaglandin and leucotriene production in ulcerative colitis. Gut (1987) 1.02
Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part I). Clin Pharmacokinet (1990) 1.01
Association between plasma concentrations of plasminogen activator inhibitor-1 and survival in patients with colorectal cancer. BMJ (1998) 1.01
Urokinase receptor in breast cancer tissue extracts. Enzyme-linked immunosorbent assay with a combination of mono- and polyclonal antibodies. Breast Cancer Res Treat (1995) 1.01
Trends in mortality, incidence and case fatality of ischaemic heart disease in Denmark, 1982-1992. Int J Epidemiol (1996) 1.01
Effect of amiloride on electrical activity and electrolyte transport in human colon. Scand J Gastroenterol (1977) 1.01
The invasive and metastatic properties of hormone-independent but hormone-responsive variants of MCF-7 human breast cancer cells. Clin Exp Metastasis (1993) 0.99
Rectal electrolyte transport and mucosal permeability in ulcerative colitis and Crohn's disease. J Lab Clin Med (1973) 0.99
Hormone resistance, invasiveness, and metastatic potential in breast cancer. Breast Cancer Res Treat (1993) 0.99
Prognostic impact of urokinase-type plasminogen activator receptor (uPAR) in cytosols and pellet extracts derived from primary breast tumours. Br J Cancer (2001) 0.99
Soluble urokinase plasminogen activator receptor measurements: influence of sample handling. Int J Biol Markers (2002) 0.99
Ultrasonic determination of liver and spleem volumes. Scand J Clin Lab Invest (1971) 0.98
Immunoassays (ELISA) of urokinase-type plasminogen activator (uPA): report of an EORTC/BIOMED-1 workshop. Eur J Cancer (1996) 0.97
Molecular analysis of two mammary carcinoma cell lines at the transcriptional level as a model system for progression of breast cancer. Clin Exp Metastasis (1998) 0.97
Time-dependent, spontaneous release of white cell- and platelet-derived bioactive substances from stored human blood. Transfusion (1996) 0.96
Plasminogen activator inhibitor type 1 in cancer: therapeutic and prognostic implications. Biol Chem Hoppe Seyler (1995) 0.96
Decreased transmural potential difference across the human rectum in ulcerative colits. Scand J Gastroenterol (1973) 0.96
Relationship of nm23 to proteolytic factors, proliferation and motility in breast cancer tissues and cell lines. Br J Cancer (1998) 0.96
Surgery for abdominal aortic aneurysms. A survey of 656 patients. J Cardiovasc Surg (Torino) (1991) 0.96
Limb salvage experience in a multidisciplinary diabetic foot unit. Diabetes Care (1999) 0.95
Hepatitis B virus infections among Danish dentists. J Infect Dis (1978) 0.95
Colonic production of nitric oxide gas in ulcerative colitis, collagenous colitis and uninflamed bowel. Scand J Gastroenterol (2002) 0.95
A secretory epithelium of the small intestine with increased sensitivity to bile acids in irritable bowel syndrome associated with diarrhoea. Scand J Gastroenterol (1978) 0.95
The effects of a constitutive expression of transforming growth factor-alpha on the growth of MCF-7 human breast cancer cells in vitro and in vivo. Mol Endocrinol (1989) 0.95
Ultrasonic diagnosis of arterial aneurysms. Scand J Thorac Cardiovasc Surg (1968) 0.95
S-phase fraction and urokinase plasminogen activator are better markers for distant recurrences than Nottingham Prognostic Index and histologic grade in a prospective study of premenopausal lymph node-negative breast cancer. J Clin Oncol (2001) 0.95
Two-dimensional gel electrophoresis analyses identify nucleophosmin as an estrogen regulated protein associated with acquired estrogen-independence in human breast cancer cells. J Steroid Biochem Mol Biol (1998) 0.95
Effect of 17 beta-oestradiol on growth curves and flow cytometric DNA distribution of two human breast carcinomas grown in nude mice. Br J Cancer (1983) 0.95
The urokinase plasminogen activator system as a target for prognostic studies in breast cancer. Breast Cancer Res Treat (1998) 0.94
Prognostic values of cathepsin B and carcinoembryonic antigen in sera of patients with colorectal cancer. Clin Cancer Res (1998) 0.94
Validation of real-time RT-PCR for analysis of human breast cancer cell lines resistant or sensitive to treatment with antiestrogens. Endocr Relat Cancer (2003) 0.94
Prostaglandin E2-mediated secretory diarrhea in villous adenoma of rectum: effect of treatment with indomethacin. Gastroenterology (1981) 0.93